

suggests ZIKV as the primary flavivirus infection. The limited antibody response in Patient 2 was presumably due to her ongoing immunosuppressive therapy. Although neither patient reported symptoms associated with ZIKV infection during the investigation, these data show evidence for ZIKV transmission by means of platelet transfusion.

Iara J.F. Motta, M.D.

Instituto Nacional de Câncer José Alencar Gomes da Silva  
Rio de Janeiro, Brazil

Bryan R. Spencer, M.P.H.

American Red Cross, Massachusetts Region  
Dedham, MA

Orlando C. Ferreira, Jr., M.D., Ph.D.

Universidade Federal do Rio de Janeiro  
Rio de Janeiro, Brazil  
orlandocfj@gmail.com

and Others

Dr. Motta and Mr. Spencer contributed equally to this letter.

A complete list of authors is available with the full text of this letter at [NEJM.org](http://NEJM.org).

Disclosure forms provided by the authors are available with the full text of this letter at [NEJM.org](http://NEJM.org).

This letter was published on August 17, 2016, at [NEJM.org](http://NEJM.org).

1. Foy BD, Kobylinski KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. *Emerg Infect Dis* 2011;17:880-2.
2. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. *Emerg Infect Dis* 2015;21:359-61.
3. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. *Euro Surveill* 2014;19(13):pii:20751.
4. Musso D, Nhan T, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. *Euro Surveill* 2014;19(14):pii:20761.
5. Lanciotti RS, Lambert AJ, Holodniy M, Saavedra S, Signor Ldel C. Phylogeny of Zika virus in Western Hemisphere, 2015. *Emerg Infect Dis* 2016;22:933-5.

DOI: 10.1056/NEJMc1607262


## Treatment Outcomes in Multidrug-Resistant Tuberculosis

**TO THE EDITOR:** Despite lengthy treatment with costly second-line drug regimens, curing multidrug-resistant (MDR) tuberculosis (bacillary resistance to at least isoniazid and rifampin) remains a challenge.<sup>1</sup> The World Health Organization (WHO) defines “cure” as “treatment completion” with at least three negative cultures after the intensive phase of therapy in the absence of “treatment failure.” The definition of “treatment failure” requires early termination of treatment or the need for permanent regimen change of at least two antituberculosis drugs. “Treatment success” is defined as the sum of cure and treatment completion.<sup>2</sup>

We evaluated treatment outcomes according to WHO definitions in the TBNET cohort of 380 patients with MDR tuberculosis at 23 European centers, including 89 patients with pre-extensively drug-resistant (XDR) tuberculosis and 33 patients with XDR tuberculosis,<sup>3,4</sup> and compared them with simplified definitions of MDR tuberculosis treatment outcomes (see the Supplementary Appendix, available with the full text of this letter at [NEJM.org](http://NEJM.org)). Cure was defined as a negative culture status 6 months after treatment initiation, no positive culture thereafter, and no relapses within 1 year after treatment completion. Treat-

ment failure was defined as a positive culture status 6 months after treatment initiation or thereafter or a relapse within 1 year after treatment completion. An undeclared outcome was defined as an outcome that was not assessed (owing to transferral out of the cohort, no culture status at 6 months while the patient was receiving care, or no post-treatment assessment). Death was defined as death during observation. Loss to follow-up was defined as nonreceipt of care 6 months after treatment initiation.

Fifty of 88 patients with treatment failure (57%) were not identified by the WHO definition. Assessment of WHO-defined cure was possible for only 13% of the patients in countries with a low incidence of tuberculosis (with a notification rate <20 per 100,000 population), 58% of the patients in countries with an intermediate incidence (with a notification rate of 20 to 100 per 100,000 population), and 52% of the patients in countries with a high incidence (with a notification rate >100 per 100,000 population), owing to a lack of sputum cultures obtained after the intensive-treatment phase. This could reflect the limited access to health care of mostly foreign-born patients or the inability of patients to produce sputum in the latter stages of therapy.



WHO-defined treatment success in MDR tuberculosis is predominantly driven by completing treatment rather than by a biologic end point and fails to address relapse-free survival as a clinically more relevant assessment of treatment efficacy.

Relapse-free cure was achieved in 61% of the patients with MDR tuberculosis, 52% of the patients with pre-XDR tuberculosis, and 39% of the patients with XDR tuberculosis when simplified definitions were used, in contrast to WHO-defined cure in 31%, 27%, and 24% of patients, respectively (Fig. 1).

Of the 318 patients with a negative culture status at 6 months, 35 (11%) reverted in the continuation phase, and 9 (3%) had a post-treatment relapse, findings that suggest that culture status at 6 months may be a reliable

predictor of relapse-free cure in patients with MDR tuberculosis.<sup>5</sup>

In conclusion, current WHO definitions may underestimate cure in patients with MDR tuberculosis. These definitions could be simplified while incorporating the assessment of post-treatment relapse.

Gunar Günther, M.D., M.P.H.  
Christoph Lange, M.D., Ph.D.

Research Center Borstel  
Borstel, Germany  
clange@fz-borstel.de

Sofia Alexandru, M.D.  
Institute of Phtisiopneumology  
Chisinau, Moldova

Neus Altet, M.D.  
Hospital Universitari Vall d'Hebron  
Barcelona, Spain

Korkut Avsar, M.D., Ph.D.

Asklepios Klinik Gauting  
Gauting, Germany

Didi Bang, M.D., Ph.D.

Statens Serum Institut  
Copenhagen, Denmark

Raisa Barbuta, M.D.

Balti Municipal Hospital  
Balti, Moldova

Graham Bothamley, M.D., Ph.D.

Homerton University Hospital  
London, United Kingdom

Ana Ciobanu, M.D.

Valeriu Crudu, M.D., Ph.D.

Institute of Phthisiopneumology  
Chisinau, Moldova

Manfred Danilovits, M.D.

Tartu University Lung Hospital  
Tartu, Estonia

Martin Dedicoat, M.D., Ph.D.

Heart of England Foundation Trust  
Birmingham, United Kingdom

Raquel Duarte, M.D., Ph.D.

Porto University  
Porto, Portugal

Gina Gualano, M.D.

Lazzaro Spallanzani National Institute for Infectious Diseases  
Rome, Italy

Heinke Kunst, M.D.

Queen Mary University Hospital  
London, United Kingdom

Wiel de Lange, M.D.

University Medical Center Groningen  
Groningen, the Netherlands

Vaira Leimane, M.D.

Riga East University Hospital  
Riga, Latvia

Cecile Magis-Escurra, M.D., Ph.D.

Radboud University Medical Center  
Nijmegen, the Netherlands

Anne-Marie McLaughlin, M.D.

St. James's Hospital  
Dublin, Ireland

Inge Muylle, M.D.

University Medical Center St. Pieter  
Brussels, Belgium

Veronika Polcová, M.D.

Thomayer University Hospital  
Prague, Czech Republic

Christina Popa, M.D.

Marius-Nasta-Institut  
Bucharest, Romania

Rudolf Rumetshofer, M.D.

Otto Wagner Hospital  
Vienna, Austria

Alena Skrahina, M.D.

Varvara Solodovnikova, M.D.

Republican Research and Practical Center for Pulmonology  
and Tuberculosis  
Minsk, Belarus

Victor Spinu, M.D.

Marius-Nasta-Institut  
Bucharest, Romania

Simon Tiberi, M.D.

Barts Health NHS Trust  
London, United Kingdom

Piret Viiklepp, M.D.

National Institute for Health Development  
Tallinn, Estonia

Frank van Leth, M.D., Ph.D.

Amsterdam Institute for Global Health and Development  
Amsterdam, the Netherlands

for TBNET

Funded by the European Commission Seventh Framework Program (FP7/2007-2013) under grant agreement FP7-223681 (TB-PANNET). Dr. Lange is supported by the German Center for Infection Research (DZIF).

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. Geneva: World Health Organization, 2015.
2. Definitions and reporting framework for tuberculosis — 2013 revision. Geneva: World Health Organization, 2013.
3. Günther G, van Leth F, Alexandru S, et al. Multidrug-resistant tuberculosis in Europe, 2010-2011. *Emerg Infect Dis* 2015; 21:409-16.
4. Günther G, van Leth F, Altet N, et al. Beyond multidrug-resistant tuberculosis in Europe: a TBNET study. *Int J Tuberc Lung Dis* 2015;19:1524-7.
5. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. *Lancet Respir Med* 2015;3:201-9.

DOI: 10.1056/NEJMc1603274

Correspondence Copyright © 2016 Massachusetts Medical Society.

#### INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere.

Letters accepted for publication will appear in print, on our website at NEJM.org, or both.

Please note the following:

- Letters in reference to a *Journal* article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article.